Abivax盘前涨超3% 投行看好其核心药物obefazimod前景

Core Viewpoint - Biotech company Abivax (ABVX.US) saw a pre-market increase of 3.58%, reaching $147.4, following an upgrade from Guggenheim, which raised the target price from $150 to $175 and maintained a "Buy" rating based on optimistic expectations for its core drug obefazimod's upcoming data release [1] Group 1 - Abivax's stock price increased by 3.58% to $147.4 in pre-market trading [1] - Guggenheim raised Abivax's target price from $150 to $175 [1] - Analyst Yatin Suneja expressed optimism regarding the data readout for obefazimod at week 44 [1]